WATCH at ₹1,804.10
Strong growth but high expectations and negative cash after capex
Watch: Track commercial conversion and cash
Home / Research / Sai Life Sciences
WATCH at ₹1,804.10
Issuer Q2 results/deck; analyst calculations
Issuer Q2 results/deck; analyst calculations
Issuer Q2 results/deck; analyst calculations
Issuer Q2 results/deck; analyst calculations
Strong growth but high expectations and negative cash after capex
Watch: Track commercial conversion and cash
Broad-based CRO and CDMO growth
Watch: Verify H2 growth
Revenue increase of ₹179 crore
Watch: Compare H2 hurdle
Rounded management mix, not separate statutory segments
Watch: Track mix and contribution
Research date: 16 November 2026 | NSE: SAILIFE | Reference price: ₹1,804.10 (Sage PRO, intraday quote, 16 November 2026)
Key takeaways
However, the same quarter reveals the tension between attractive long-duration demand and the cost of building capacity ahead of utilisation. First-half reported capital expenditure of ₹621 crore is more than three times statutory operating cash flow of ₹190 crore. Borrowings excluding leases increased from ₹95.13 crore in March to ₹448.24 crore in September.
At ₹1,804.10, FY26 basic EPS ₹16.63 implies 108.5x P/E; H1 EPS ₹8.09 annualised implies 111.5x. After November option allotment, approximately 21.258 crore shares imply equity value ₹38,352 crore. Chapter 6 details scenario hurdles.
Key takeaways
CDMO includes late-stage and commercial production, with a particular small-molecule capability. The strategic value of the platform is knowledge continuity: when an existing discovery customer progresses, the supplier may already understand the molecule, experimental history, impurity controls and cost drivers. This can shorten transfer time and lower the client's execution risk. It is not a legal guarantee that the customer awards the next stage.
The September deck identifies 300+ active customers, including 19 of the top 25 global pharma companies by market cap, 4,400+ employees, and research/manufacturing across Hyderabad, Bidar, Manchester and Boston. Its 34 commercial NCEs, 14 Phase III/pre-registration molecules, five discovery-to-market molecules and 50+ advanced programmes indicate pipeline depth, not disclosed product-level cash flows.
One late-phase molecule moved to commercial in Q2; gross progression does not mean the net commercial count grew. Track conversion, repeat sales and attrition. Peptides, ADCs and oligonucleotides expand technical opportunity but require validated processes and customer orders before earning a commercial valuation.
CRO needs skilled billable teams and laboratory utilisation; CDMO needs qualified reactors, quality systems and commercial volume. The integrated model can deepen customer lifetime value, yet a strategic framework is not a committed order book.
Compared with Anthem's higher-margin commercial mix and Syngene's broader discovery/biologics footprint, Sai's case rests on concurrent CRO/CDMO growth and conversion of its new small-molecule capacity. Compare incremental return, cash conversion and qualified utilisation, not a single sector multiple.
Key takeaways
| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 | H1 FY27 | H1 FY26 | FY26 |
|---|---|---|---|---|---|---|
| Operating revenue | 658.59 | 554.29 | 537.47 | 1212.87 | 1033.89 | 2192.49 |
| Other income | 3.97 | 3.54 | 15.33 | 7.51 | 25.23 | 49.13 |
| Materials + inventory change | 174.69 | 144.91 | 140.12 | 319.60 | 281.23 | 570.89 |
| Employee expense | 198.06 | 179.90 | 162.79 | 377.96 | 323.41 | 683.06 |
| Other expenses | 99.45 | 81.47 | 88.73 | 180.92 | 162.49 | 307.39 |
| Operating EBITDA, derived | 186.38 | 148.00 | 145.84 | 334.39 | 266.76 | 631.15 |
| Depreciation/amortisation | 48.13 | 45.94 | 39.75 | 94.07 | 77.47 | 166.86 |
| Finance cost | 10.94 | 7.64 | 9.35 | 18.58 | 21.72 | 39.24 |
| PBT before exception | 131.28 | 97.97 | 112.05 | 229.25 | 192.80 | 474.19 |
| PBT after exception | 131.28 | 97.97 | 112.05 | 229.25 | 192.80 | 466.19 |
| Tax | 32.96 | 24.69 | 28.21 | 57.65 | 48.50 | 117.28 |
| PAT | 98.32 | 73.29 | 83.84 | 171.60 | 144.30 | 348.91 |
| Basic EPS, Rs | 4.63 | 3.46 | 4.01 | 8.09 | 6.91 | 16.63 |
Accounting check: derived operating EBITDA is operating revenue less cost of materials plus inventory movement, employee expense and other expenses; it excludes all other income and adds back neither an arbitrary adjustment nor OCI. The statutory PBT bridge is operating EBITDA + other income − depreciation − finance costs − exceptional items.
For Q2: ₹186.38 + ₹3.97 − ₹48.13 − ₹10.94 = ₹131.28 crore. Management shows EBITDA including forex of ₹187 crore versus ₹156 crore in Q2 FY26 and ₹335 crore versus ₹281 crore in H1. The statutory derived operating EBITDA is therefore not identical to management's metric, especially in prior periods.
Comparisons use a consistent definition. Statutory derived margin is 28.3% Q2 versus 27.1% prior year; the issuer's rounded EBITDA margin is 28% versus 29%. This is not a contradiction when definitions differ.
Q2 revenue increased by ₹121.12 crore YoY and ₹104.30 crore sequentially. Growth was 22.5% YoY and 18.8% QoQ. H1 revenue increased 17.3%, while FY26 revenue was ₹2,192.49 crore. Q2 sales growth was broad-based: management reports CDMO +20% and CRO +28%. Based on rounded Q2 mix of 64% CDMO and 36% CRO, approximately ₹421.5 crore and ₹237.1 crore of sales respectively; these are inferred estimates, not independently reported statutory segment figures. H1 mix is 62% CDMO/38% CRO, implying approximately ₹752 crore and ₹461 crore. The company reports one operating segment under Ind AS 108; therefore do not present management business mix as separate audited segment accounts.
Employee expenses increased ₹35.27 crore YoY, about 21.7%, broadly in line with sales. Materials plus inventory change increased ₹34.57 crore, about 24.7%, somewhat above revenue. Other expenses increased ₹10.72 crore, about 12.1%, supporting operating leverage.
Derived EBITDA rose approximately ₹40.54 crore, or 27.8%; incremental margin on additional sales roughly 33.5%. Q2 PBT grew 17.2% and PAT 17.3%, below sales growth, because depreciation increased and other income declined substantially.
Q2 PAT margin was 14.9% versus 15.6% last year. New assets generate depreciation before peak production; management EBITDA can look healthy while per-share cash outcomes lag.
H1 CFO after tax was ₹190.13 crore versus ₹92.84 crore, more than doubling. This is approximately 111% of PAT versus 64% last year. Pre-working-capital operating cash was ₹345.61 crore versus ₹283.28 crore; working-capital and other operating adjustments reduced the amount before tax to ₹214.14 crore. Inventory consumed ₹91.08 crore and other current assets consumed ₹60.79 crore; receivables released ₹19.78 crore versus a prior-year use of ₹136.47 crore. The current cash improvement partly reflects easier collection comparison and should not be extrapolated as a permanent doubling in operating cash.
Statutory cash purchases of PPE, intangible assets and associated capital items were ₹561.29 crore in H1, versus ₹247.61 crore. CFO less those purchases was negative ₹371.16 crore, versus negative ₹154.77 crore.
This is a transparent cash proxy before financing, not audited free cash flow to equity. Management-reported H1 capex of ₹621 crore is not identical to cash purchases: differences may reflect accruals, timing, capital creditors and scope.
Use statutory cash flow for liquidity and management capex for execution; do not subtract both. On management capex basis, CFO minus spend is negative ₹430.87 crore. Both demonstrate an investment-intensive year.
Key takeaways
September borrowings: non-current ₹30.31 crore plus current ₹417.94 crore, total ₹448.24 crore; March equivalents ₹20.50 crore and ₹74.62 crore, total ₹95.13 crore. Leases total ₹171.33 crore versus ₹193.33 crore.
Cash and equivalents are ₹30.92 crore, other bank balances ₹28.56 crore and current investments ₹48.48 crore; do not automatically classify all financial assets as freely available cash. A conservative narrow net debt excluding leases is borrowings minus cash, ₹417.32 crore, versus ₹13.21 crore in March.
Including leases and subtracting cash gives ₹588.65 crore. Borrowings/equity approximately 16.7% versus 3.8%. Current assets ₹1,440.53 crore and current liabilities ₹1,184.75 crore imply 1.22x current ratio versus 1.69x in March.
A large part of current assets consists of other current assets and inventory; this is not an equivalent cash coverage ratio. Short-term refinancing and working-capital discipline deserve monitoring.
Inventory rose from ₹150.97 crore to ₹242.05 crore, current receivables fell from ₹373.62 crore to ₹342.22 crore and trade payables (MSME + other) fell from ₹285.34 crore to ₹272.80 crore. The simple inventory plus receivables less payables proxy rose from ₹239.25 crore to ₹311.47 crore.
Cash-flow changes differ from period-end changes due to currency and other reconciliations. Approximate receivables days using annualised H1 sales and September ending receivables are 51.5 days, not contractual DSO.
Monitor unbilled contract assets in other current assets, inventory linked to firm orders, ageing and collections. A growing commercial pipeline may legitimately require inventory, but capital committed before qualification or demand introduces risk.
The issuer reports ₹621 crore H1 FY27 capital spend, ₹358 crore in Q2, and a ₹1,100–1,300 crore full-year plan. H2 residual implied spend is ₹479–679 crore; midpoint ₹579 crore. The first-half investment is 51.2% of revenue and 185.4% of management EBITDA. These ratios will not remain economically attractive without a meaningful ramp or subsequent capex moderation.
Bidar's additional 220 KL small-molecule capacity is ready and completing quality trials, with management expecting revenue contribution during FY27. The additional 225 KL phase is now expected early Q3 FY28 rather than the earlier timeline.
Management links the shift to project prioritisation and says it does not expect FY28 revenue commitments to be affected. This is a forecast, not evidence of completed utilisation. A new Telangana site is in design, with groundbreaking expected Q4 FY27.
These three projects have distinct milestones and cash obligations: ready/qualify/produce, deferred capacity commissioning, and design/break ground. Model them separately, and do not capitalise all future plant sales in FY27.
On ₹1,200 crore illustrative FY27 capex, a 15% post-tax incremental return requires ₹180 crore annual NOPAT after assets mature. At 25% tax this is ₹240 crore EBIT. With an analyst assumption of ₹90–120 crore incremental depreciation, incremental EBITDA needs ₹330–360 crore. At 30% incremental operating margin, approximately ₹1,100–1,200 crore incremental annual sales are required. At 25% margin, ₹1,320–1,440 crore. This is a capital hurdle, not management guidance; some capex replaces existing assets or builds capabilities rather than directly creating a new sales stream. The calculation nevertheless illustrates the importance of project-linked return and timing. If capacity ramps slowly, the company can incur depreciation, fixed operating costs and borrowing interest before realising cash. An investment committee should request a reconciliation of growth capex, maintenance capex, productive commissioning, qualification and realised commercial contribution.
Key takeaways
The first integrated collaboration is expected to be fully functional during Q3. The correct tracking metric is not number of partnerships alone but billable work, cross-sell across functions, retention and commercial progression. Broad service coverage can increase customer lifetime value, while concentration can rise if a few strategic customers dominate incremental capacity. Ask for aggregate revenue mix and top-customer exposure rather than demanding confidential contract details.
FY26 H2 sales were ₹1,158.60 crore. A 20% FY27 growth illustration requires ₹1,418.12 crore H2 (+22.4% YoY); 25% growth requires ₹1,527.75 crore (+31.9%). Repeating Q2 sales twice yields approximately ₹2,530 crore FY27, +15.4%. These analyst bridges are not guidance.
During the call management discussed raw material and solvent pressure linked to supply disruption, with efforts to recover costs from customers. Pass-through mechanisms differ by contract, and timing matters.
An initial cost increase can compress quarterly contribution even if recoverable later. Monitor material margin, receivable ageing and customer recoveries rather than assuming every increase is immediately offset.
The company stated capacity commissioning has been reprioritised according to customer requirements. A delay can be disciplined if demand timing shifts, but can also weaken revenue ramp if qualification is later than expected.
The decisive evidence will be commercial batch commencement and realised revenue.
Key takeaways
| FY28 assumption | Bear | Base | Bull |
|---|---|---|---|
| Revenue, ₹cr | 3000 | 3600 | 4200 |
| Operating EBITDA margin | 24% | 29% | 32% |
| Operating EBITDA, ₹cr | 720 | 1044 | 1344 |
| Other income | 15 | 20 | 25 |
| D&A | 300 | 330 | 360 |
| Finance cost | 55 | 45 | 40 |
| PBT | 380 | 689 | 969 |
| PAT after 25% tax | 285 | 516.75 | 726.75 |
| EPS on 21.5 crore shares | 13.26 | 24.03 | 33.80 |
| Illustrative P/E | 35x | 50x | 65x |
| Implied value, ₹ | 464 | 1202 | 2197 |
| Versus ₹1804.10 | -74% | -33% | +22% |
The bear case models capacity and funding costs outrunning revenue: PAT below FY26 despite larger revenue. The base case assumes robust 28% compound sales growth and good operating absorption, but even that earnings trajectory requires a very high multiple for the reference price to offer a favourable return.
The bull case assumes successful customer conversion, strong commercial supply and 32% operating margin; it also relies on the market preserving 65x FY28 earnings. Scenario multiples are analytical assumptions, not historical norms or observed peer values.
The estimates exclude dividends and discounting and are not probability-weighted targets.
Reverse underwriting at 50x: price ₹1,804.10 requires EPS ₹36.08, PAT ₹775.76 crore on 21.5 crore shares. At 25% tax PBT must be ₹1,034.35 crore. Add base D&A and finance, subtract other income: required operating EBITDA ₹1,389.35 crore.
At 29% margin, sales required ₹4,791 crore, implying FY26-FY28 CAGR about 48%. At 65x, reference price requires EPS ₹27.76, or PAT about ₹597 crore; with base cost assumptions, required sales about ₹3,971 crore.
The hurdle depends heavily on terminal multiple. A high valuation may persist if commercial growth becomes durable and cash returns prove strong, but that is precisely the evidence investors must demand.
Key takeaways
(3) Scientific risk: clinical failure, product launch timing and commercial allocation can interrupt expected conversion. (4) Customer concentration: strategic contracts may increase exposure to a small group; track aggregate concentration, diversification and repeat demand. (5) Cost/quality: solvent inflation, pass-through delays, inspections, contamination or data integrity; monitor official regulatory and quality disclosures. (6) Margin/valuation: cost absorption may improve, but multiple compression can erase operating gains. (7) Dilution: stock option allotments change EPS denominator. (8) Currency: separate operating margin from forex and hedge/OCI items. (9) Reinvestment: negative cash after capital purchases may persist during growth capex; require a path to owner cash after commissioning.
S1. Sai Life Sciences, 5 November 2026 board-approved Q2/H1 FY27 financial results, consolidated statement, balance sheet, cash flow, notes and limited review: Statutory text and the consolidated P&L page visually checked; financial calculations use the consolidated tables. S2. Investor presentation dated 5 November 2026, filed 6 November: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=15530947-ecd4-4f8d-99b5-3d59b47f1e78.pdf. Sage PRO canonical 75651, current semantic ACCEPT and full-token scored. Operational mix, 67% utilisation, pipeline, capex, customer and capacity evidence. S3. Earnings call held 6 November, available 12 November: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=89557f77-2b3c-497b-99e7-f2bb3b3a05cf.pdf. Canonical 90392, current semantic ACCEPT and full-token scored. Integrated service versus programme, 220/225 KL timing, material costs and H2 outlook. S4. Issuer earnings release, 5 November 2026: Reconciles management rounded revenue, EBITDA and PAT. S5. Q1 FY27 investor presentation, available 11 August: https://www.bseindia.com/xml-data/corpfiling/AttachHis/9b86f38d-7a42-4a09-8c5d-4bf013f94a85.pdf (9746). Q1 call: https://www.bseindia.com/xml-data/corpfiling/AttachHis/597af4ad-26ff-4921-8230-e5c8bcc718f3.pdf (9747). Statutory Q1 comparative columns are the financial baseline. S6. Sage PRO price observation 16 November 2026, ₹1,804.10. Intraday quote, not certified closing price; refresh before investing.
This source-verified longform is not independently QA-approved. Full source-page parity, independently verified peer multiples and owner-cash DCF remain open.
Issuer Q2 results/deck; analyst calculations
Issuer Q2 results/deck; analyst calculations
Issuer Q2 results/deck; analyst calculations
Issuer Q2 results/deck; analyst calculations
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.